"The findings supplement previous results from the PARTNER 3 trial, which found that patients who underwent a transcatheter aortic valve replacement, or TAVR - a minimally invasive procedure in which the narrowed aortic valve is replaced via percutaneous access with wires and catheters through the femoral artery - demonstrated similar five-year survival rates to patients who underwent traditional aortic-valve replacement surgery."
"TAVR is a reasonable option for patients with aortic stenosis with outcomes similar to surgical aortic-valve replacement at seven years. There may be a signal for better survival in surgical aortic valve replacement,"
"Aortic stenosis occurs when the opening of the aortic valve narrows and restricts blood flow from the left ventricle to the aorta. More than 13 percent of Americans over the age of 75 have aortic stenosis, according to the American Heart Association, and is most commonly caused by aging as calcium or scarring damages the aortic valve, restricting blood flow."
Patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) showed seven-year survival outcomes similar to those who underwent surgical aortic-valve replacement. Prior PARTNER 3 results demonstrated similar five-year survival for TAVR compared with surgery. TAVR is a minimally invasive procedure performed via percutaneous femoral access using wires and catheters to replace the narrowed aortic valve. The trial randomized 1,000 low-surgical-risk patients to TAVR or surgical replacement and followed them for seven years. Two primary endpoints measured composites of death, stroke, or rehospitalization related to the procedure, the valve, or heart failure.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]